Pyxis Oncology, Inc. 8K

Pyxis Oncology reported Q2 2026 results, detailed clinical progress for MICVO in head and neck cancer, and completed a private placement financing that extends its cash runway into Q2 2027.

Pyxis Oncology, Inc. reported its second quarter 2026 financial results and provided an update on its lead asset MICVO, including progress in Phase 1 monotherapy and Phase 1/2 combination trials for recurrent/metastatic head and neck squamous cell carcinoma, while also announcing completion of a private placement of up to $114 million (with approximately $50 million received upfront) that, together with existing cash, extends its projected cash runway into the second quarter of 2027. The company completed target enrollment in the Phase 1 Part 2 monotherapy dose expansion, plans to disclose updated monotherapy data in Fall 2026 and updated KEYTRUDA (pembrolizumab) combination data in Q4 2026, and reported increased net loss year over year driven primarily by higher general and administrative expenses, including severance and stock-based compensation. As of June 30, 2026, Pyxis held $34.5 million in cash, cash equivalents (including restricted cash) and short-term investments, and subsequently closed the private placement on July 2, 2026, supporting continued clinical development and longer patient follow-up for MICVO.

Filing Facts

CIK

1782223

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-347911

Alert Tier

6